Methods to treat dysregulated blood glucose disorders

1. A method for treating a dysregulated blood glucose disorder in a mammal in need thereof comprising administering an effective amount of an N-methyl-D-aspartate receptor activator or a pharmaceutically acceptable salt thereof to the mammal in need thereof.

2. The method of claim 1 , wherein the N-methyl-D-aspartate receptor activator is a functional agonist at the glycine binding site on the N-methyl-D-aspartate receptor.

3. The method of claim 1 , wherein the N-methyl-D-aspartate receptor activator binds to the glycine binding site on the N-methyl-D-aspartate receptor.

4. The method of claim 1 , wherein the N-methyl-D-aspartate receptor activator is D-serine, D-cycloserine or glycine or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the N-methyl-D-aspartate receptor activator is D-serine or a pharmaceutically acceptable salt thereof.

6. The method of claim 1 , wherein the dysregulated blood glucose disorder is hyperglycemia.

7. The method of claim 6 , wherein the hyperglycemia is caused by pancreatitis, pancreatic cancer, hyperthyroidism, Cushing's syndrome, glucagonoma, pheochromocytoma, stress episodes, medication side-effects or pregnancy or insulin resistance or insulin deficiency.

8. The method of claim 6 , wherein the hyperglycemia is caused by insulin resistance.

9. The method of claim 1 , wherein the dysregulated blood glucose disorder is diabetes.

10. The method of claim 1 , further comprising administering insulin to the mammal.

11. The method of claim 10 , wherein the N-methyl-D-aspartate receptor activator or the pharmaceutically acceptable salt thereof and the insulin are co-administered.

12. The method of claim 1 , further comprising administering a D-amino acid oxidase inhibitor or a pharmaceutically acceptable salt thereof to the mammal.

13. The method of claim 1 , further comprising administering a antidiabetic agent or a pharmaceutically acceptable salt thereof to the mammal.

14. A pharmaceutical composition comprising an N-methyl-D-aspartate receptor activator or a pharmaceutically acceptable salt-thereof, insulin and a pharmaceutically acceptable carrier.

15. The pharmaceutical composition of claim 14 , wherein the N-methyl-D-aspartate receptor activator is D-serine, D-cycloserine or glycine or a pharmaceutically acceptable salt thereof.

16. The pharmaceutical composition of claim 14 , wherein the N-methyl-D-aspartate receptor activator is D-serine or a pharmaceutically acceptable salt thereof.

17. The pharmaceutical composition of claim 14 , further comprising a D-amino acid oxidase inhibitor or a pharmaceutically acceptable salt thereof.